Fluitran


Combined with:

Diovan
Lasix
Norvasc

Indications and Reactions:

Role Indications Reactions
Secondary
Hypertension 38.1%
Drug Use For Unknown Indication 10.9%
Lumbar Spinal Stenosis 7.0%
Diabetes Mellitus 5.3%
Cerebral Infarction 4.3%
Hyperlipidaemia 4.3%
Gastric Ulcer 4.0%
Large Intestine Carcinoma 4.0%
Oedema 3.4%
Drug Exposure During Pregnancy 3.2%
Cardiovascular Disorder 2.1%
Chronic Obstructive Pulmonary Disease 1.9%
Headache 1.9%
Urine Output Decreased 1.9%
Constipation 1.7%
Diuretic Effect 1.3%
Product Used For Unknown Indication 1.3%
Renal Hypertension 1.3%
Gastritis 1.1%
Hypercholesterolaemia 1.1%
Eosinophil Count Increased 12.7%
Respiratory Failure 7.9%
Hyponatraemia 6.3%
Lacunar Infarction 6.3%
Urinary Tract Infection 6.3%
Blood Creatine Phosphokinase Increased 4.8%
Cerebral Infarction 4.8%
Hepatic Function Abnormal 4.8%
Hepatitis 4.8%
Renal Impairment 4.8%
Self-medication 4.8%
Solitary Kidney 4.8%
White Blood Cell Count Decreased 4.8%
Hypoglycaemia 3.2%
Intestinal Obstruction 3.2%
Papuloerythroderma Of Ofuji 3.2%
Pseudoaldosteronism 3.2%
Red Blood Cell Count Decreased 3.2%
Small For Dates Baby 3.2%
White Blood Cell Count Increased 3.2%
Concomitant
Hypertension 40.4%
Product Used For Unknown Indication 6.0%
Drug Use For Unknown Indication 5.9%
Prophylaxis 5.5%
Rheumatoid Arthritis 5.2%
Diabetes Mellitus 4.9%
Cardiac Failure 4.7%
Cardiac Failure Chronic 2.8%
Constipation 2.7%
Chronic Hepatitis C 2.7%
Angina Pectoris 2.2%
Pulmonary Hypertension 2.2%
Pulmonary Arterial Hypertension 2.1%
Hyperuricaemia 2.1%
Hyperlipidaemia 2.0%
Insomnia 1.9%
Oedema 1.7%
Gastritis 1.7%
Type 2 Diabetes Mellitus 1.7%
Metastatic Renal Cell Carcinoma 1.6%
Vomiting 10.5%
Renal Impairment 8.3%
Pneumonia 7.3%
White Blood Cell Count Decreased 7.0%
Interstitial Lung Disease 6.0%
Liver Disorder 5.7%
Renal Failure Acute 5.4%
Death 5.1%
Platelet Count Decreased 4.8%
Sepsis 4.8%
Cerebral Infarction 4.4%
Rash 4.4%
Thrombocytopenia 3.8%
Pyrexia 3.5%
Blood Urea Increased 3.2%
Renal Failure 3.2%
Right Ventricular Failure 3.2%
Shock 3.2%
Toxic Epidermal Necrolysis 3.2%
Urinary Tract Infection 3.2%

Drug Data